The HBV Specially-Related Long Noncoding RNA HBV-SRL Involved in the Pathogenesis of Hepatocellular Carcinoma

Author:

Zhang Cunzhen1ORCID,Lu Lei2ORCID,Xin Haibei1ORCID,Zhang Minfeng1ORCID,Ding Zhiwen1ORCID,Li Qiaomei1ORCID,Chen Kuang3ORCID,Hu Minggen3ORCID,Liu Shupeng4ORCID,Li Nan1ORCID

Affiliation:

1. Department of Hepatic Surgery I (Ward I) Shanghai Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China

2. Changhai Hospital, Second Military Medical University, Shanghai, China

3. Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China

4. Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China

Abstract

Hepatitis B virus (HBV) is one of the major risk factors for HCC (hepatocellular carcinoma) occurrence with a diverse role in the pathogenesis of HCC. More works need to be performed to elucidate a more thorough understanding of the molecular mechanisms involving in HBV-induced HCC, although some mechanisms such as genome integration have been reported. In the present study, aberrantly expressed lncRNAs were identified between HCC tumor tissues with or without HBV infection. Among these molecules, HBV specially-related long noncoding RNA (HBV-SRL) was further found to correlate with poor prognosis and a shorter overall survival time in HCC patients with HBV infection. Additionally, HBV-SRL was found function as oncogene by upregulating the NF-κB2 expression. These data suggest that HBV infection altered gene expression pattern in liver cells which contributed to HBV-related HCC development, and HBV-SRL may serve as a new molecular marker or potential therapeutic target of HBV-related HCC.

Funder

National Key Sci-Tech Special Project of China

Publisher

Hindawi Limited

Subject

Oncology

Reference35 articles.

1. Epidemiology and surveillance for hepatocellular carcinoma: New trends

2. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection

3. Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 calgb 80802 randomized clinical trial;G. K. Abou-Alfa;JAMA Oncology,2019

4. HBV-TERT promoter integration harnesses host ELF4 resulting in TERT gene transcription in hepatocellular carcinoma;K. M. Sze;Hepatology,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3